Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2019 2
2020 1
2021 6
2022 5
2023 8
2024 8
2025 9
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models.
Schoutrop E, Poiret T, El-Serafi I, Zhao Y, He R, Moter A, Henriksson J, Hassan M, Magalhaes I, Mattsson J. Schoutrop E, et al. J Immunother Cancer. 2023 Feb;11(2):e005691. doi: 10.1136/jitc-2022-005691. J Immunother Cancer. 2023. PMID: 36746513 Free PMC article.
MSLN-CAR T cell treatment efficacy was evaluated by survival analysis and the characterization and quantification of the different MSLN-CAR T cells were performed by flow cytometry, quantitative PCR and gene expression analysis. ...CONCLU …
MSLN-CAR T cell treatment efficacy was evaluated by survival analysis and the characterization and quantification of th …
Challenges of Anti-Mesothelin CAR-T-Cell Therapy.
Zhai X, Mao L, Wu M, Liu J, Yu S. Zhai X, et al. Cancers (Basel). 2023 Feb 21;15(5):1357. doi: 10.3390/cancers15051357. Cancers (Basel). 2023. PMID: 36900151 Free PMC article. Review.
This article reviews the clinical research status, obstacles, advancements and challenges of anti-MSLN CAR-T-cell therapy. Clinical trials on anti-MSLN CAR-T cells show that they have a high safety profile but limited efficacy. At present …
This article reviews the clinical research status, obstacles, advancements and challenges of anti-MSLN CAR-T-cell thera …
Mesothelin-targeted CAR-T cell therapy for solid tumors.
Klampatsa A, Dimou V, Albelda SM. Klampatsa A, et al. Expert Opin Biol Ther. 2021 Apr;21(4):473-486. doi: 10.1080/14712598.2021.1843628. Epub 2020 Nov 12. Expert Opin Biol Ther. 2021. PMID: 33176519 Free article. Review.
This review focuses on anti-MSLN chimeric antigen receptor (CAR) T cell immunotherapy approaches.Areas covered: A brief overview of MSLN as a therapeutic target and existing anti-MSLN antibody-based drugs and vaccines is provided. A detailed account of anti-MSLN CAR …
This review focuses on anti-MSLN chimeric antigen receptor (CAR) T cell immunotherapy approaches.Areas covered: A brief overview of MSLN as …
Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity.
Yang Y, Vedvyas Y, Alcaina Y, Trumper SJ, Babu DS, Min IM, Tremblay JM, Shoemaker CB, Jin MM. Yang Y, et al. JCI Insight. 2024 Nov 22;9(22):e186268. doi: 10.1172/jci.insight.186268. JCI Insight. 2024. PMID: 39576012 Free PMC article.
Mesothelin (MSLN) has been identified as a target antigen for CAR T cell treatment of mesothelioma, lung, ovarian, and other cancers because of its high expression on tumor cells and limited expression on mesothelial cells. ...
Mesothelin (MSLN) has been identified as a target antigen for CAR T cell treatment of mesothelioma, lung, ovarian, and other cancers …
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma.
Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ. Castelletti L, et al. Biomark Res. 2021 Feb 15;9(1):11. doi: 10.1186/s40364-021-00264-1. Biomark Res. 2021. PMID: 33588928 Free PMC article. Review.
Clinical trials using anti-MSLN CAR T cells in MM have shown that this potential therapeutic is relatively safe. ...They include local (intratumoral) delivery of anti-MSLN CAR T cells, improved CAR design and co-stimulation, and measures …
Clinical trials using anti-MSLN CAR T cells in MM have shown that this potential therapeutic is relatively safe. ...The …
Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies.
Sun Y, Yang H, Xu Q, Li X, Lou J, Duan J, Xu J, Liu Z, Xia Y, Lin Z, Li L, Sun D, Li J, Liu T, Guo J, Xu W, Zhu W, Liu Y, Sun B, Zhong J, Rong L, Qian Q, Xu C, Wang J. Sun Y, et al. Adv Sci (Weinh). 2026 Jun;13(35):e08754. doi: 10.1002/advs.202508754. Epub 2025 Oct 24. Adv Sci (Weinh). 2026. PMID: 41134065 Free PMC article.
Malignant mesothelioma (MM) is an aggressive and currently incurable cancer with limited therapeutic options. ...These findings suggest that NAC-T cell therapy represents a promising therapeutic strategy for patients with malignant mesothelioma....
Malignant mesothelioma (MM) is an aggressive and currently incurable cancer with limited therapeutic options. ...These findings sugge …
Mesothelin-Specific CAR T Cells Target Ovarian Cancer.
Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, Magalhaes I, Mattsson J. Schoutrop E, et al. Cancer Res. 2021 Jun 1;81(11):3022-3035. doi: 10.1158/0008-5472.CAN-20-2701. Epub 2021 Apr 1. Cancer Res. 2021. PMID: 33795251
New therapeutic options for patients with ovarian cancer are urgently needed. Therefore, we evaluated the efficacy of two second-generation mesothelin (MSLN)-directed CAR T cells in orthotopic mouse models of ovarian cancer. ...Altogether, our study de …
New therapeutic options for patients with ovarian cancer are urgently needed. Therefore, we evaluated the efficacy of two seco …
Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, Li J, Chen Z, Jiang L, Zhang Y, Shi R, Ma L, Jia S, Zhang Y, Zhang Q, Liang J, Yao S, Hu Z, Guo Z. Chen J, et al. Cancer Immunol Immunother. 2023 Feb;72(2):409-425. doi: 10.1007/s00262-022-03238-w. Epub 2022 Aug 4. Cancer Immunol Immunother. 2023. PMID: 35925286 Free PMC article.
We demonstrated the efficacy of our anti-MSLN CAR-T cells for ovarian cancer treatment in an in vitro experiment to kill ovarian tumor cell lines. ...Then, we demonstrated the efficacy of anti-MSLN CAR-T cells in an in vivo …
We demonstrated the efficacy of our anti-MSLN CAR-T cells for ovarian cancer treatment in an in vitro exp …
Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality.
Schoutrop E, Renken S, Micallef Nilsson I, Hahn P, Poiret T, Kiessling R, Wickström SL, Mattsson J, Magalhaes I. Schoutrop E, et al. Oncoimmunology. 2022 Jun 28;11(1):2093426. doi: 10.1080/2162402X.2022.2093426. eCollection 2022. Oncoimmunology. 2022. PMID: 35898704 Free PMC article.
Mesothelin (MSLN) has emerged as an attractive target for CAR T cell therapy of several solid malignancies, including ovarian cancer. To improve clinical response rates with MSLN-CAR T cells, a better understanding of the mechanisms impacting CA …
Mesothelin (MSLN) has emerged as an attractive target for CAR T cell therapy of several solid malignancies, including ovarian canc …
Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies.
Zhang YC, Li XY, Deng Q, Ge YJ, Yi RR, Wang HJ, Wang JT, Zhou H, Kong XF, Liu RJ, Zhang YT, Li XP, He XW, Zhu HY. Zhang YC, et al. Theranostics. 2024 Sep 30;14(16):6249-6267. doi: 10.7150/thno.97590. eCollection 2024. Theranostics. 2024. PMID: 39431011 Free PMC article.
We inserted the antibody sequence into the chimeric antigen receptor (CAR) construct to induce MSLN CAR-T cells to secret the CD39 antibody, and the efficacy was measured in xenograft models of ovarian cancer. ...We also observed increased CD39 …
We inserted the antibody sequence into the chimeric antigen receptor (CAR) construct to induce MSLN CAR-T cells to secr …
38 results